OBJECTIVE: Meta-analysis was used to synthesize results of studies on emotional consequences of predictive genetic testing for BRCA1/2 mutations conferring increased risk of breast and ovarian cancer. DESIGN: Studies assessing anxiety or cancer-specific distress before and after provision of test results (k = 20) were analyzed using a random-effects model. Moderator variables included country of data collection and personal cancer history of study participants. MAIN OUTCOME MEASURES: Standardized mean gain effect sizes were calculated for mutation carriers, noncarriers, and those with inconclusive results over short (0-4 weeks), moderate (5-24 weeks), or long (25-52 weeks) periods of time after testing. RESULTS: Distress among carriers increased shortly after receiving results and returned to pretesting levels over time. Distress among noncarriers and those with inconclusive results decreased over time. Some distress patterns differed in studies conducted outside the United States and for individuals with varying cancer histories. CONCLUSION: Results underscore the importance of time; changes in distress observed shortly after test-result disclosure frequently differed from the pattern of distress seen subsequently. Although emotional consequences of this testing appear minimal, it remains possible that testing may affect cognitive and behavioral outcomes, which have rarely been examined through meta-analysis. Testing may also affect understudied subgroups differently.
OBJECTIVE: Meta-analysis was used to synthesize results of studies on emotional consequences of predictive genetic testing for BRCA1/2 mutations conferring increased risk of breast and ovarian cancer. DESIGN: Studies assessing anxiety or cancer-specific distress before and after provision of test results (k = 20) were analyzed using a random-effects model. Moderator variables included country of data collection and personal cancer history of study participants. MAIN OUTCOME MEASURES: Standardized mean gain effect sizes were calculated for mutation carriers, noncarriers, and those with inconclusive results over short (0-4 weeks), moderate (5-24 weeks), or long (25-52 weeks) periods of time after testing. RESULTS: Distress among carriers increased shortly after receiving results and returned to pretesting levels over time. Distress among noncarriers and those with inconclusive results decreased over time. Some distress patterns differed in studies conducted outside the United States and for individuals with varying cancer histories. CONCLUSION: Results underscore the importance of time; changes in distress observed shortly after test-result disclosure frequently differed from the pattern of distress seen subsequently. Although emotional consequences of this testing appear minimal, it remains possible that testing may affect cognitive and behavioral outcomes, which have rarely been examined through meta-analysis. Testing may also affect understudied subgroups differently.
Authors: R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem Journal: Nature Date: 1995 Dec 21-28 Impact factor: 49.962
Authors: Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding Journal: Science Date: 1994-10-07 Impact factor: 47.728
Authors: C Lerman; S Narod; K Schulman; C Hughes; A Gomez-Caminero; G Bonney; K Gold; B Trock; D Main; J Lynch; C Fulmore; C Snyder; S J Lemon; T Conway; P Tonin; G Lenoir; H Lynch Journal: JAMA Date: 1996-06-26 Impact factor: 56.272
Authors: Willem Eijzenga; Daniela E E Hahn; Neil K Aaronson; Irma Kluijt; Eveline M A Bleiker Journal: J Genet Couns Date: 2013-08-31 Impact factor: 2.537
Authors: Ashley H Woodson; Kimberly I Muse; Heather Lin; Michelle Jackson; Danielle N Mattair; Leslie Schover; Terri Woodard; Laurie McKenzie; Richard L Theriault; Gabriel N Hortobágyi; Banu Arun; Susan K Peterson; Jessica Profato; Jennifer K Litton Journal: Oncologist Date: 2014-06-20
Authors: Kristin M Kostick; Cody Brannan; Stacey Pereira; Gabriel Lázaro-Muñoz Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2018-10-25 Impact factor: 3.568